1. Bladder Cancer: Highlights from 2006
Antonio Alcaraz 
European Urology Supplements 
Volume 6, Issue 12, Pages (July 2007)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Cancer-free survival rate after treatment with Bacillus Calmette-Guérin (BCG)+interferon-alpha (IFN-α) is similar in BCG-naïve patients (BCG-N) and patients with recurrent bladder cancer after 12 mo of remission. * Versus BCG-N patients.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Results from interactive voting on a representative case (details: see text) indicate that six instillations of Bacillus Calmette-Guérin (BCG) therapy and cystectomy are the favoured treatment options, whereas BCG+interferon-alpha (IFN-α) and optimised mitomycin therapy are less chosen therapies.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Results from interactive voting indicate that approximately an equal amount of participants chose between chemotherapy (chemo), Bacillus Calmette-Guérin (BCG) therapy, or a combination of both as the treatment option for a patient with bladder cancer previously treated with BCG (details outlined in text), whereas radical cystectomy was a less favoured option.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

5. Fig. 4
Bladder recurrence, local recurrence, distant metastases and disease-free 2-yr survival rates after laparoscopic nephroureterectomy (LNU) and open nephroureterectomy (ONU) are comparable.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions